Armistice Capital, LLC Increases Stake in GlucoTrack, Inc. to 4.99%

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A with the SEC, reporting an increased stake in GlucoTrack, Inc. (GCTK). The filing reveals that the reporting persons now beneficially own 102,115 shares of common stock, representing 4.99% of the company. This is a notable increase from a previously reported 0.0% ownership position. Armistice Capital, LLC, a Delaware limited liability company, serves as the investment manager for the Armistice Capital Master Fund, which has the right to receive dividends and proceeds from the sale of these securities. Steven Boyd, as the managing member of Armistice Capital, LLC, shares voting and dispositive power over the shares. The filing was made pursuant to Rule 13d-1(b), indicating the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The event triggering this amendment occurred on March 31, 2026.